Abstract
Non-Hodgkin lymphomas (NHL) are a groups of malignancies with high heterogeneity, originated from T lymphocytes and B lymphocytes, and B lymphocytes counts for 85% approximately. With the improvement of diagnosis, treatment, and prognosis, most NHL patients can achieve long-term remission, but curative effect of some relapsed or refractory patients are still not optimistic. Recently, there is a huge development in the treatment of relapsed or refractory NHL patients with adoptive cellular immunotherapy (ACT), especially chimeric antigen receptor T cells (CAR-T). CAR-T targeting specific tumor antigens CD19, CD20, CD30, etc., is becoming a new approach of NHL clinical treatment. This article reviews research progress of construction of CAR-T and its clinical efficacy and safety in the treatment of NHL, and function optimization. Key words: Lymphoma, non-Hodgkin; Chimeric antigen receptor T cell; Adoptive cellular immunotherapy
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Transfusion and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
